Activity Overview
To provide an enduring record of the most important contents from the live HDL Highlights Symposium: Translating HDL Science to Clinical Practice, held in New York City in May 2011, the National Lipid Association has partnered with Elsevier to publish an open-access, journal-indexed Internet activity, with optional CME/CE credit, presented as a slide-driven narrative with edited text for each figure interpolated from the audio presentations. This online publication from the Journal of Clinical Lipidology provides the opportunity to access the contents visually, acoustically, and via the peer-reviewed text, as presented during this key opinion leader symposium.
Target Audience
This journal publication is designed for a broader audience of healthcare professionals including lipidologists, cardiologists, endocrinologists, internists, primary care physicians, pharmacists, nurse practitioners, physician assistants, nurses, and registered dietitians.
Learning Objectives
Upon completion of this activity, participants should be able to:- Evaluate the role of HDL-C in reducing cardiovascular events and rates of atherosclerotic disease progression;
- Describe the metabolic pathways of HDL and the roles that HDL and inflammation play in the development of atherosclerosis;
- Distinguish those patients who remain at risk for CV events despite having an acceptable LDL level;
- Identify appropriate current treatment options including concomitant drug therapy to minimize residual CV risk;
- Summarize recent lipid-related research on raising HDL cholesterol and emerging treatment options, and clinical implications for patient management.
Faculty
 |
M. John Chapman, BS, PhD, DSc President, European Atherosclerosis Society Director, INSERM (Dyslipidemia and Atherosclerosis Research) Paris, France |
 |
Ernst J. Schaefer, MD, FNLA Distinguished University Professor Tufts University School of Medicine Boston, MA |
 |
Daniel J. Rader, MD, FNLA Professor of Medicine University of Pennsylvania Philadelphia, PA |
 |
Philip J. Barter, MD, PhD Director, The Heart Research Institute Sydney, Australia |
 |
Robert S. Rosenson, MD, FNLA Professor of Medicine, Mt Sinai School of Medicine Director, Cardiometabolic Disorders Mt Sinai Heart New York, NY |
|
View Program and Claim CME/CE Credit |
View Program without Claiming CME/CE Credit |